

# **BBS-Bioactive Bone Substitutes Plc applies for its shares to be listed on the Nasdaq First North Finland and the Nasdaq First North Sweden marketplaces**

BBS-BIOACTIVE BONE SUBSTITUTES PLC COMPANY ANNOUNCEMENT 16 FEBRUARY 2018 AT 12:30 P.M. EET

*Not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa, Singapore, Japan, New Zealand or any other country, in which the publication or distribution of this presentation would be unlawful.*

BBS-Bioactive Bone Substitutes Plc (the "BBS", "Company") has today filed a listing application with Nasdaq Helsinki Ltd and Nasdaq OMX Stockholm AB to list the Company's shares on the First North Finland and First North Sweden marketplaces. Trading in the shares is expected to begin on the First North Finland marketplace under the share trading code "BONEH" and on the First North Sweden marketplace under the share trading code "BONES" on or about 28 February 2018.

Aalto Capital Partners Plc in Finland and Stockholm Certified Advisers AB in Sweden act as the Company's Certified Advisors under First North Nordic Rulebook.

Further enquiries:

Pekka Jalovaara, CEO,  
tel. +358 50 5529275, e-mail: [pekka.jalovaara@bbs-artebone.fi](mailto:pekka.jalovaara@bbs-artebone.fi)

Hannu Säynäjäkangas, CFO,  
tel. +358 40 5021092, e-mail: [hannu.saynajakangas@bbs-artebone.fi](mailto:hannu.saynajakangas@bbs-artebone.fi)

Hanna Tölli, Production Manager,  
tel. +358 40 0953131, e-mail: [hanna.tolli@bbs-artebone.fi](mailto:hanna.tolli@bbs-artebone.fi)

Certified Advisors:

First North Finland: Aalto Capital Partners Oy, tel. +358 40 5477 007

First North Sweden: Stockholm Certified Advisers AB, tel. +46 70 5516 729

*BBS-Bioactive Bone Substitutes Plc ("BBS") is the health technology company operating since 2003. Before that there was a background of seven years of medical research in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE® product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own*

production plant located in Reisjärvi and it is approved by FIMEA. *More information: [www.bbs-artebone.fi](http://www.bbs-artebone.fi).*

#### DISTRIBUTION

Nasdaq Helsinki Ltd  
Nasdaq Stockholm Ltd  
Main media

#### Disclaimer:

*This presentation does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. No part of the initial public offering concerning the securities is registered in the United States, and the securities will not be offered to the public in the United States.*

*In connection with the Company's possible initial public offering, with respect to each Member State of the European Economic Area other than Finland and Sweden, and which has implemented the Prospectus Directive (each, a "Relevant Member State"), no action will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, in connection with the Company's possible initial public offering, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression an "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied by any measure implementing the Prospectus Directive in that Relevant Member State. The expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.*

*This announcement is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.*